Alzamend Neuro is trading 7.04% higher at $1.51 after hours on November 6, 2026, following a regular-session close of $1.41; no clear company-specific catalyst was identified. - The company’s available press-release feed lists no November 6 release. - Earlier coverage linked regular-session weakness to biotech-sector pressure, not a company-specific announcement; that context does not explain the after-hours gain.